References
- Boussios S, Ozturk MA, Moschetta M, Karathanasi A, Zakynthinakis-Kyriakou N, Katsanos KH, Christodoulou DK, Pavlidis N. The developing story of predictive biomarkers in colorectal cancer. JPM. 2019;9(1):12. doi:https://doi.org/10.3390/jpm9010012
- Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33(17):1974–82. doi:https://doi.org/10.1200/JCO.2014.59.4358
- Zhang S, Zhong M, Wang C, Xu Y, Gao WQ, Zhang Y. CCL5-deficiency enhances intratumoral infiltration of CD8+ T cells in colorectal cancer. Cell Death Dis. 2018;9(7):766. doi:https://doi.org/10.1038/s41419-018-0796-2
- Jifu E, Yan F, Kang Z, Zhu L, Xing J, Yu E. CD8 + CXCR5+ T cells in tumor-draining lymph nodes are highly activated and predict better prognosis in colorectal cancer. Hum Immunol. 2018;79(6):446–52. doi:https://doi.org/10.1016/j.humimm.2018.03.003
- Fakih M, Ouyang C, Wang C, Tu TY, Gozo MC, Cho M, Sy M, Longmate JA, Lee PP. Immune overdrive signature in colorectal tumor subset predicts poor clinical outcome. J Clin Invest. 2019;129(10):4464–76. doi:https://doi.org/10.1172/JCI127046
- Li S, Sun Y, Huang J, Wang B, Gong Y, Fang Y, Liu Y, Wang S, Guo Y, Wang H, et al. Anti-tumor effects and mechanisms of Astragalus membranaceus (AM) and its specific immunopotentiation: status and prospect. J Ethnopharmacol. 2020;258:112797. doi:https://doi.org/10.1016/j.jep.2020.112797
- Wang G, Wang YZ, Yu Y, Wang JJ. Inhibitory ASIC2-mediated calcineurin/NFAT against colorectal cancer by triterpenoids extracted from Rhus chinensis Mill. J Ethnopharmacol. 2019;235:255–67. doi:https://doi.org/10.1016/j.jep.2019.02.029
- Wang G, Wang YZ, Yu Y, Wang JJ, Yin PH, Xu K. Triterpenoids extracted from Rhus chinensis Mill act against colorectal cancer by inhibiting enzymes in glycolysis and glutaminolysis: network analysis and experimental validation. Nutr Cancer. 2020a;72(2):293–319. doi:https://doi.org/10.1080/01635581.2019.1631858
- Wang G, Wang YZ, Yu Y, Yin PH, Xu K. The antitumor activity of betulinic acid-loaded nanoliposomes against colorectal cancer in vitro and in vivo via glycolytic and glutaminolytic pathways. J Biomed Nanotechnol. 2020b;16(2):235–51. doi:https://doi.org/10.1166/jbn.2020.2888
- Dutta D, Chakraborty B, Sarkar A, Chowdhury C, Das P. A potent betulinic acid analogue ascertains an antagonistic mechanism between autophagy and proteasomal degradation pathway in HT-29 cells. BMC Cancer. 2016;16:23. doi:https://doi.org/10.1186/s12885-016-2055-1
- Ray AL, Berggren KL, Restrepo Cruz S, Gan GN, Beswick EJ. Inhibition of MK2 suppresses IL-1β, IL-6, and TNF-α-dependent colorectal cancer growth. Int J Cancer. 2018;142(8):1702–11.
- Sinha P, Chornoguz O, Clements VK, Artemenko KA, Zubarev RA, Ostrand-Rosenberg S. Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL. Blood. 2011;117(20):5381–90. doi:https://doi.org/10.1182/blood-2010-11-321752
- Flynn J, Gorry P. Flow cytometry analysis to identify human CD8+ T cells. Methods Mol Biol. 2019;2048:1–13. doi:https://doi.org/10.1007/978-1-4939-9728-2_1
- Luo W, Liao WJ, Ma L, Huang YT, Shi M, Wen Q, Wang XN. Dynamic monitoring the TCR CDR3 spectratypes in patients with metastatic CRC treated with a combination of bevacizumab, irinotecan, fluorouracil, and leucovorin. Cancer Immunol Immunother. 2010;59(2):247–56. doi:https://doi.org/10.1007/s00262-009-0745-0
- West NR, McCuaig S, Franchini F, Powrie F. Emerging cytokine networks in colorectal cancer. Nat Rev Immunol. 2015;15(10):615–29. doi:https://doi.org/10.1038/nri3896
- Schwiebs A, Radeke HH. Immunopharmacological activity of betulin in inflammation-associated carcinogenesis. Anticancer Agents Med Chem. 2018;18(5):645–51. doi:https://doi.org/10.2174/1871520617666171012124820
- Zhao J, Li R, Pawlak A, Henklewska M, Sysak A, Wen L, Yi JE, Obmińska-Mrukowicz B. Antitumor activity of betulinic acid and betulin in canine cancer cell lines. In Vivo. 2018;32(5):1081–8. doi:https://doi.org/10.21873/invivo.11349
- Nicolov M, Ghiulai RM, Voicu M, Mioc M, Duse AO, Roman R, Ambrus R, Zupko I, Moaca EA, Coricovac DE, et al. Cocrystal formation of betulinic acid and ascorbic acid: Synthesis, physico-chemical assessment, antioxidant, and antiproliferative activity. Front Chem. 2019;7:92. doi:https://doi.org/10.3389/fchem.2019.00092
- Zheng Y, Liu P, Wang N, Wang S, Yang B, Li M, Chen J, Situ H, Xie M, Lin Y, et al. Betulinic acid suppresses breast cancer metastasis by targeting GRP78-mediated glycolysis and ER stress apoptotic pathway. Oxid Med Cell Longev. 2019;2019:8781690. doi:https://doi.org/10.1155/2019/8781690
- Kim PS, Kwilas AR, Xu W, Alter S, Jeng EK, Wong HC, Schlom J, Hodge JW. IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas . Oncotarget. 2016;7(13):16130–45. doi:https://doi.org/10.18632/oncotarget.7470
- Zhou XM, Li WQ, Wu YH, Han L, Cao XG, Yang XM, Wang HF, Zhao WS, Zhai WJ, Qi YM, et al. Intrinsic expression of immune checkpoint molecule TIGIT could help tumor growth in vivo by suppressing the function of NK and CD8+ T cells. Front Immunol. 2018;9:2821. doi:https://doi.org/10.3389/fimmu.2018.02821
- Krijgsman D, de Vries NL, Skovbo A, Andersen MN, Swets M, Bastiaannet E, Vahrmeijer AL, van de Velde CJH, Heemskerk MHM, Hokland M, et al. Characterization of circulating T-, NK-, and NKT cell subsets in patients with colorectal cancer: the peripheral blood immune cell profile. Cancer Immunol Immunother. 2019;68(6):1011–24. doi:https://doi.org/10.1007/s00262-019-02343-7
- Sconocchia G, Eppenberger S, Spagnoli GC, Tornillo L, Droeser R, Caratelli S, Ferrelli F, Coppola A, Arriga R, Lauro D, et al. NK cells and T cells cooperate during the clinical course of colorectal cancer. Oncoimmunology. 2014;3(8):e952197. doi:https://doi.org/10.4161/21624011.2014.952197
- Kuhn S, Yang J, Hyde EJ, Harper JL, Kirman JR, Ronchese F. IL-1βR-dependent priming of antitumor CD4+ T cells and sustained antitumor immunity after peri-tumoral treatment with MSU and mycobacteria. Oncoimmunology. 2015;4(10):e1042199. doi:https://doi.org/10.1080/2162402X.2015.1042199
- Lin D, Lei L, Liu Y, Zhang Y, Hu B, Bao G, Song Y, Jin Z, Liu C, Mei Y, et al. Membrane IL1α inhibits the development of hepatocellular carcinoma via promoting T- and NK-cell activation. Cancer Res. 2016;76(11):3179–88. doi:https://doi.org/10.1158/0008-5472.CAN-15-2658
- Scheper W, Kelderman S, Fanchi LF, Linnemann C, Bendle G, de Rooij MAJ, Hirt C, Mezzadra R, Slagter M, Dijkstra K, et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nat Med. 2019;25(1):89–94. doi:https://doi.org/10.1038/s41591-018-0266-5
- Yao Y, Wang X, Zhou H, Zhang H, Shi Y, Wang S, Wang X. MHC class II peptides induce CD8 + CD44 + Ly49+ regulatory T cells in C57BL/6 mice. Cell Immunol. 2017;312:71–7. doi:https://doi.org/10.1016/j.cellimm.2016.11.005
- Bozzetti F. Comments on: why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies, Andreyev et al., Eur J Cancer 1998, 34, pp. 503-509. Eur J Cancer. 1998;34(13):2132–3. doi:https://doi.org/10.1016/s0959-8049(98)00263-9
- Capasso A, Lang J, Pitts TM, Jordan KR, Lieu CH, Davis SL, Diamond JR, Kopetz S, Barbee J, Peterson J, et al. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. J Immunother Cancer. 2019;7(1):37. doi:https://doi.org/10.1186/s40425-019-0518-z
- Yaghoubi N, Soltani A, Ghazvini K, Hassanian SM, Hashemy SI. PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer. Biomed Pharmacother. 2019;110:312–8. doi:https://doi.org/10.1016/j.biopha.2018.11.105
- Chowdhury PS, Chamoto K, Honjo T. Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy. J Intern Med. 2018;283(2):110–20. doi:https://doi.org/10.1111/joim.12708
- Rajan A, Heery CR, Thomas A, Mammen AL, Perry S, O’Sullivan Coyne G, Guha U, Berman A, Szabo E, Madan RA, et al. Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma. J Immunother Cancer. 2019;7(1):269.
- Zhao X, Subramanian S. Oncogenic pathways that affect antitumor immune response and immune checkpoint blockade therapy. Pharmacol Ther. 2018;181:76–84. doi:https://doi.org/10.1016/j.pharmthera.2017.07.004
- Bertheloot D, Latz E. HMGB1, IL-1α, IL-33 and S100 proteins: dual-function alarmins. Cell Mol Immunol. 2017;14(1):43–64. doi:https://doi.org/10.1038/cmi.2016.34